Showing 3671-3680 of 5646 results for "".
- Eyenovia Launches Clobetasol for Postoperative Ocular Surgery Pain and Inflammationhttps://modernod.com/news/eyenovia-launches-clobetasol-for-postoperative-ocular-surgery-pain-and-inflammation/2482460/Eyenovia announced the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, which is designed to address postoperative inflammation and pain following ocular surgeries. The FDA approval and launch marks the first new ophthalmic steroid to be a
- Hoya Highlights the Impact Rural vs Urban Living Environments May Have On Myopia In Young Childrenhttps://modernod.com/news/hoya-highlights-the-impact-rural-vs-urban-living-environments-may-have-on-myopia-in-young-children/2482457/Hoya Vision Care announced the results of a 5-year epidemiological study conducted in Scotland exploring the correlations between myopia, socio-economic deprivation, and urban or rural dwellings in young children. The study, which reviewed refractive error data from eye examinations in
- Neuro-Optometric Rehabilitation Association Appoints Barbara Barclay as New Executive Directorhttps://modernod.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/The Neuro-Optometric Rehabilitation Association, International (NORA), has announced the appointment of Barbara Barclay as its new executive director, effective October 1. Ms. Barclay, an expert in eye-tracking technology and health tech, brings more than 30 years of leadership experience, i
- Lumibird Unveils Omnicad Imaging Platform for Ocular Surface Diseasehttps://modernod.com/news/lumibird-unveils-omnicad-imaging-platform-for-ocular-surface-disease/2482453/Lumibird Medical announced the launch of the Omnicad, an imaging platform equipped with integrated AI algorithms designed to aid in the diagnosis of ocular surface disease (OSD). The device, exclusively available in the US market, aims to address the needs of optometrists and ophthalmol
- Opthea Completes Manufacturing Milestone for Wet AMD Treatmenthttps://modernod.com/news/opthea-completes-manufacturing-milestone-for-wet-amd-treatment/2482447/Opthea announced the successful completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, its lead candidate for treating wet age-related macular degeneration (AMD). The PPQ campaign involved the production of three consecutive commercial-scale
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- iCare Launches ST500 Slit-Lamp Based Tonometerhttps://modernod.com/news/icare-launches-st500-slit-lamp-based-tonometry/2482436/iCare announced the release of the iCare ST500, a slit-lamp-based tonometer that brings the features of iCare’s rebound tonometry technology into a modern design. The iCare ST500 offers an advanced solution for IOP measurement, combining extreme ease of u
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed